Key result
Cardiac myosin inhibitors significantly reduced resting LVOT gradient (MD -37.64; 95% CI -46.71 to -28.56) and improved peak oxygen consumption and patient-reported outcomes in HCM patients.
Why the study?
Current management strategies for hypertrophic cardiomyopathy have significant limitations and risks, while recently emerging cardiac myosin inhibitors have shown promise as noninvasive treatment options.
Do cardiac myosin inhibitors improve LVOT gradients, biomarkers, and symptoms in patients with hypertrophic cardiomyopathy?
Meta-Analysis (n=826)
Do cardiac myosin inhibitors improve LVOT gradients, biomarkers, and symptoms in patients with hypertrophic cardiomyopathy?
Cardiac myosin inhibitors significantly improve LVOT gradients, biomarkers, exercise capacity, and symptoms in patients with hypertrophic cardiomyopathy, with a manageable safety profile.
Answers are grounded in this paper and cite their sources.
Supports CMI consideration in obstructive HCM; confirms pooled RCT efficacy and extends evidence for routine use.
Hypertrophic cardiomyopathy (HCM) is a genetic cardiac disorder characterized by structural and functional abnormalities. Current management strategies, such as medications and septal reduction therapies, have significant limitations and risks. Recently, cardiac myosin inhibitors (CMIs) like mavacamten and aficamten have shown promise as noninvasive treatment options. This meta-analysis aims to evaluate the efficacy and safety of CMIs in HCM patients. PubMed/MEDLINE, Embase, the Cochrane Library, Ovid, and ClinicalTrials.gov were searched for randomized controlled trials (RCTs) that compared CMIs to control treatments in HCM patients from inception till June 15, 2024. A random-effects model was used to pool odds ratios (ORs) for dichotomous outcomes and mean differences (MDs) for continuous outcomes along with the corresponding 95% confidence intervals (CIs). Heterogeneity was assessed using the χ2 test and Higgins I2 statistic, and sensitivity and subgroup analyses were performed. Six RCTs involving 826 patients were included. CMI therapy significantly reduced resting left ventricular outflow tract (LVOT) gradient (MD, -37.64; 95% CI, -46.71 to -28.56), Valsalva LVOT gradient (MD, -46.04; 95% CI, -57.60 to -34.48), post-exercise LVOT peak gradient (MD, -48.64; 95% CI, -68.20 to -28.88), N-terminal pro-b-type natriuretic peptide levels (MD, -1.05; 95% CI, -1.64 to -0.47), and cardiac troponin I levels (MD, -7.96; 95% CI, -12.84 to -3.07). Improvements were observed in peak oxygen consumption (MD, 1.20; 95% CI, 0.23-2.17) and patient-reported outcomes (Kansas City Cardiomyopathy Questionnaire Clinical Summary Score: MD, 6.44; 95% CI, 3.50-9.37), with more patients achieving New York Heart Association class improvement >1 (OR, 4.05; 95% CI, 2.61-6.30). Treatment-emergent adverse events were higher with CMI therapy (OR, 1.45; 95% CI, 1.02-2.05), but serious adverse events and other safety outcomes were comparable in both groups. CMIs, including mavacamten and aficamten, significantly improve clinical outcomes in HCM patients with a manageable safety profile. These results indicate that CMIs offer a promising noninvasive alternative to septal reduction therapies.
No takes yet. Share an insight, caveat, or question.
Ahsan et al. (2024) conducted a meta-analysis in Hypertrophic cardiomyopathy (n=826). Cardiac myosin inhibitors (mavacamten and aficamten) vs. Control treatments was evaluated on Resting left ventricular outflow tract (LVOT) gradient (MD -37.64, 95% CI -46.71 to -28.56). Cardiac myosin inhibitors significantly reduced resting LVOT gradient (MD -37.64; 95% CI -46.71 to -28.56) and improved peak oxygen consumption and patient-reported outcomes in HCM patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: